SCHEMBL1637074

SCHEMBL1637074

COc1ccc(S(=O)(=O)Oc2cc(NS(=O)(=O)/C=C/c3c(OC)cc(OC)cc3OC)ccc2OC)cc1

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.47
ALDH1A1 P00352 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.45
HTT P42858 4/20 0.45
MAPK1 P28482 2/20 0.45
HPGD P15428 1/20 0.45
PLAU P00749 2/20 0.43
MAPT P10636 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CYP1A1 P04798 1/20 0.40
CYP1B1 Q16678 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
PKM P14618 1/20 0.40
ALOX15 P16050 1/20 0.40
CYP19A1 P11511 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1634428 0.94 ALDH1A1 (0.45) LMNAALDH1A1SMN1; SMN2HTTMAPK1
SCHEMBL1122446 0.84 ALDH1A1 (0.63) LMNAALDH1A1SMN1; SMN2HTTMAPK1
SCHEMBL1634729 0.82 LMNA (0.44) LMNAALDH1A1SMN1; SMN2HTTMAPK1
SCHEMBL1635270 0.81 LMNA (0.38) LMNAALDH1A1SMN1; SMN2HTTMAPT
SCHEMBL1634025 0.81 CA12 (0.54) LMNAALDH1A1SMN1; SMN2HTTMAPK1
SCHEMBL1634646 0.80 HPGD (0.44) LMNAALDH1A1MAPK1HPGDMAPT
SCHEMBL1635811 0.80 PLK1 (0.46) LMNAALDH1A1SMN1; SMN2HTTMAPK1
SCHEMBL1635815 0.80 PLK1 (0.46) LMNAALDH1A1SMN1; SMN2HTTMAPK1
SCHEMBL1634057 0.80 LMNA (0.43) LMNAALDH1A1SMN1; SMN2HTTMAPK1
SCHEMBL1634052 0.80 LMNA (0.43) LMNAALDH1A1SMN1; SMN2HTTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080058290-A1 Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2008-03-06 US claimed
EP-3138832-A1 SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS Temple University - Of The Commonwealth System of Higher Education (US) 2017-03-08 EP disclosed
US-7932242-B2 Anticancer agents; radiation and chemical resistance TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-04-26 US disclosed
US-20080058290-A1 Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058290-A1 Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders PCNA, MKI67, TP53 LMNA 2048/4885ALDH1A1 564/4885SMN1; SMN2 2736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.